Retinal Imaging: Eligible participants will undergo one retinal imaging session of both eyes for the following:
* Single field stereo color fundus photography (cFP) - pre and post dilation
* Macular spectral domain-optical coherence tomography (SD-OCT)
Study summary
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
* Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
* Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
Exclusion Criteria:
* Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
* Unable to acquire adequate quality images, as evaluated by the Central Reading Center
* Severe vision loss requiring urgent surgery
* Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
* A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
* Unwilling to sign informed consent form
* Currently or previously enrolled in an interventional AMD clinical trial
Primary outcome measure(s)
AMD Classification by Participant Count — up to 18 months A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by classifying AMD status.
The goal is to have:
* 20% participants with no AMD
* 30% participants with Early AMD
* 30% participants with Intermediate AMD
* 10% participants with Geographic Atrophy (GA)
* 10% participants with Neovascular age-related macular degeneration (nAMD)
Geographic Location by Participant Count — up to 18 months A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by geographic location. 1000 participants from up to 25 global sites will be included.
Trial sites (14)
Facility
City
Region
Status
Bergstrom Eye Research LLC
Fargo
North Dakota
Recruiting
Erie Retina Research
Erie
Pennsylvania
Recruiting
Retina Foundation of the Southwest
Dallas
Texas
Recruiting
Valley Retina Institute
McAllen
Texas
Recruiting
Retina Consultants of Texas (Houston)
The Woodlands
Texas
Recruiting
University of Utah - John A. Moran Eye Center
Salt Lake City
Utah
Recruiting
University Station Eye Care Clinic
Madison
Wisconsin
Recruiting
Charles Research Center
Buenos Aires
Argentina
Not Yet Recruiting
Adelaide Eye and Retina Centre
Adelaide
Australia
Not Yet Recruiting
Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.